Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors

Liu, Min; Sun, Qian; Wei, Feng; Ren, Xiubao

doi:10.20892/j.issn.2095-3941.2020.0112

Cited by 8 publications

(4 citation statements)

References 84 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IgA+ B cells continuously overexpress PD-L1, producing large amounts of IL-10 and TGF- β and has immunosuppressive effect on the proliferation and function of CD8+T cells. This suggests that PD-L1+B cells may be a subset of Bregs and play a powerful immunosuppressive function against T cell reaction ( 54 ).…”

Section: Role Of the Pd-1/pd-l1 Pathway In The Tumor Microenvironment...mentioning

confidence: 99%

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

Han

Yang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a long time, but there are still many shortcomings. In recent years, with the deepening of research on tumor immune microenvironment, researchers have begun to explore new approaches in immunotherapy, and the introduction of immune checkpoint inhibitors has brought fundamental changes to the treatment of HCC. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that plays an important role in down-regulating immune system function and promoting tolerance. Programmed cell death ligand 1 (PDL-1) is involved in tumor immune evasion by binding to PD-1, resulting in failure of treatment. Currently, immunotherapy targeting the PD-1/PD-L1 axis has achieved unprecedented success in HCC, but it also faces great challenges, with its low remission rate still to be solved. For most patients with HCC, the PD-1/PD-L1 pathway is not the only rate limiting factor of antitumor immunity, and blocking only the PD-1/PD-L1 axis is not enough to stimulate an effective antitumor immune response; thus, combination therapy may be a better option. In this study, changes in the immune microenvironment of HCC patients were reviewed to clarify the feasibility of anti-PD-1/PD-L1 therapy, and a series of monotherapy and combination therapy clinical trials were summarized to verify the safety and efficacy of this newly developed treatment in patients with advanced HCC. Furthermore, we focused on hyperprogressive disease and drug resistance to gain a better understanding of PD-1/PD-L1 blockade as a promising treatment.

show abstract

Section: Role Of the Pd-1/pd-l1 Pathway In The Tumor Microenvironment...mentioning

confidence: 99%

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

Han

Yang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The immune checkpoint blockade of PD-1 and PD-L1 pathway has emerged as one of the most potential therapeutic strategies in a variety of cancers, such as head and neck squamous cell carcinoma, non-small cell lung cancer, advanced esophageal squamous cell carcinoma, renal cell carcinoma, etc. [ 10 , 11 , 13 – 15 ]. Several monoclonal antibodies against PD-1 and PD-L1, such as nivolumab, cemiplimab, pembrolizumab, atezolizumab, etc., have been proved to be effective in the management of several malignancies [ 13 , 14 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review

Zhou

Mao

et al. 2021

BMC Oral Health

View full text Add to dashboard Cite

Background Antibodies to PD-1 and PD-L1 have remarkably improved the overall survival of many patients with advanced solid tumors. SHR-1210 is an anti-PD-1 monoclonal antibody. Dermatologic reactive capillary hemangiomas (RCH) were the most common and unique drug-related AEs of SHR-1210, but rare on oral mucosa and gastrointestinal mucosa. Herein we report a case of RCH occurred in oral mucosa during the clinical trials of SHR-1210 in the treatment of non-small cell lung cancer. Case presentation A male in his 60 s with a history of non-small cell lung cancer received injection of anti-PD-1 monoclonal antibodies SHR-1210. The patient developed drug-related RCH on skin after the first injection and began to have gingival hyperplasia one year after the first injection which gradually increased in size and affect eating and speaking. Anti-PD-1 treatments were continued. After periodontal treatment, two oral lesions and one skin lesion were surgically removed. Similar histological manifestation was found in all three lesions as reactive capillary hemangiomas. All lesions had a good prognosis without recurrence on oral mucosa within one year after surgery. Conclusions Oral reactive capillary hemangiomas could be induced by SHR-1210 in the treatment of non-small cell lung cancer. Surgical resection is an effective treatment with a good prognosis.

show abstract

“…Recently, ICI therapy has achieved impressive results in the treatment of various malignancies 20 . Immune checkpoints tightly regulate immune system functioning 21 . Immune checkpoints either promote T cell activation and induce an immune response (stimulatory immune checkpoint molecules) or inhibit the immune response and prevent autoimmunity (inhibitory immune checkpoint molecules), thereby naturally regulating the human immune system.…”

Section: Tme Phenotype and The Impact On Immunotherapymentioning

confidence: 99%

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors

Liu,

Li,

Qin

et al. 2023

Cancer Biol Med

View full text Add to dashboard Cite

Cancer remains a significant global health challenge with limited treatment options beyond systemic therapies, such as chemotherapy, radiotherapy, and molecular targeted therapy. Immunotherapy has emerged as a promising therapeutic modality but the efficacy has plateaued, which therefore provides limited benefits to patients with cancer. Identification of more effective approaches to improve patient outcomes and extend survival are urgently needed. Drug repurposing has emerged as an attractive strategy for drug development and has recently garnered considerable interest. This review comprehensively analyses the efficacy of various repurposed drugs, such as transforming growth factor-beta (TGF-β) inhibitors, metformin, receptor activator of nuclear factor-κB ligand (RANKL) inhibitors, granulocyte macrophage colony-stimulating factor (GM-CSF), thymosin α1 (Tα1), aspirin, and bisphosphonate, in tumorigenesis with a specific focus on their impact on tumor immunology and immunotherapy. Additionally, we present a concise overview of the current preclinical and clinical studies investigating the potential therapeutic synergies achieved by combining these agents with immune checkpoint inhibitors.

show abstract

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors

Cited by 8 publications

References 84 publications

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors

Contact Info

Product

Resources

About